5370 related articles for article (PubMed ID: 3561923)
1. In vitro and in vivo enhancement of vincristine antitumor activity on B16 melanoma cells by calcium antagonist flunarizine.
Bellelli A; Camboni C; de Luca G; Materazzi M; Mattioni M; Sezzi ML; Bellelli L
Oncology; 1987; 44(1):17-23. PubMed ID: 3561923
[TBL] [Abstract][Full Text] [Related]
2. Effects of a calcium-antagonist (flunarizine) on the in vitro growth of B16 mouse melanoma cells.
Sezzi ML; Zupi G; De Luca G; Materazzi M; Bellelli L
Anticancer Res; 1984; 4(4-5):229-34. PubMed ID: 6091526
[TBL] [Abstract][Full Text] [Related]
3. Effects of a calcium-antagonist (flunarizine) on cancer cell movement and phagocytosis.
Sezzi ML; De Luca G; Materazzi M; Bellelli L
Anticancer Res; 1985; 5(3):265-71. PubMed ID: 4015040
[TBL] [Abstract][Full Text] [Related]
4. Verapamil potentiation of doxorubicin resistance development in B16 melanoma cells both in vitro and in vivo.
Formelli F; Supino R; Cleris L; Mariani M
Br J Cancer; 1988 Apr; 57(4):343-7. PubMed ID: 3390370
[TBL] [Abstract][Full Text] [Related]
5. Sodium ascorbate enhancement of carbidopa-levodopa methyl ester antitumor activity against pigmented B16 melanoma.
Pierson HF; Meadows GG
Cancer Res; 1983 May; 43(5):2047-51. PubMed ID: 6831435
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a doxorubicin-resistant murine melanoma line: studies on cross-resistance and its circumvention.
Supino R; Prosperi E; Formelli F; Mariani M; Parmiani G
Br J Cancer; 1986 Jul; 54(1):33-42. PubMed ID: 3730255
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the effects of vinblastine, vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro.
Jordan MA; Himes RH; Wilson L
Cancer Res; 1985 Jun; 45(6):2741-7. PubMed ID: 3986806
[TBL] [Abstract][Full Text] [Related]
8. Promotion by verapamil of vincristine responsiveness in tumor cell lines inherently resistant to the drug.
Tsuruo T; Iida H; Naganuma K; Tsukagoshi S; Sakurai Y
Cancer Res; 1983 Feb; 43(2):808-13. PubMed ID: 6848194
[TBL] [Abstract][Full Text] [Related]
9. In vivo characterization of a doxorubicin resistant B16 melanoma cell line.
Formelli F; Rossi C; Supino R; Parmiani G
Br J Cancer; 1986 Aug; 54(2):223-33. PubMed ID: 3741758
[TBL] [Abstract][Full Text] [Related]
10. PTD4-apoptin protein and dacarbazine show a synergistic antitumor effect on B16-F1 melanoma in vitro and in vivo.
Jin JL; Gong J; Yin TJ; Lu YJ; Xia JJ; Xie YY; Di Y; He L; Guo JL; Sun J; Noteborn MH; Qu S
Eur J Pharmacol; 2011 Mar; 654(1):17-25. PubMed ID: 21184754
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of Ru(III) complexes carrying beta-diketonato ligands in vitro and in vivo.
Arandjelovic SS; Bjelogrlic KS; Malesevic NN; Tesic LjZ; Radulovic SS
J BUON; 2009; 14(2):271-9. PubMed ID: 19650178
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the in vitro and in vivo effects of retinoids either alone or in combination with cisplatin and 5-fluorouracil on tumor development and metastasis of melanoma.
Liu X; Chan SY; Ho PC
Cancer Chemother Pharmacol; 2008 Dec; 63(1):167-74. PubMed ID: 18465132
[TBL] [Abstract][Full Text] [Related]
13. Opposite effects on tumor growth depending on dose of an immunomodulatory polysaccharide with or without cyclophosphamide.
Leibovici J; Kopel S; Wolman M
Anticancer Res; 1985; 5(5):553-8. PubMed ID: 4062258
[TBL] [Abstract][Full Text] [Related]
14. Dipyridamole augments the antitumor effects of fluorinated pyrimidines.
Sakaguchi Y; Kusumoto T; Kusumoto H; Maehara Y; Furusawa M; Sugimachi K
Anticancer Res; 1992; 12(1):119-21. PubMed ID: 1567156
[TBL] [Abstract][Full Text] [Related]
15. Cell survival in B16 melanoma after treatment with combinations of cytotoxic agents: lack of potentiation.
Stephens TC; Peacock JH; Steel GG
Br J Cancer; 1977 Jul; 36(1):84-93. PubMed ID: 889685
[TBL] [Abstract][Full Text] [Related]
16. Sequential chemoimmunotherapy with cisplatin, interferon-beta and interleukin-2 inhibits the growth of B16-F1 melanoma in syngeneic mice.
Kubo H; Matsumoto K; Funahashi M; Takagi H; Kitajima Y; Taniguchi S; Saida T
Melanoma Res; 2000 Jun; 10(3):223-9. PubMed ID: 10890375
[TBL] [Abstract][Full Text] [Related]
17. Quantitative evaluation of anticancer agents against human melanoma cells implanted in nude mice.
Lockshin A; Giovanella BC; Stehlin JS
Exp Cell Biol; 1986; 54(3):149-54. PubMed ID: 3743866
[TBL] [Abstract][Full Text] [Related]
18. Reversal of resistance to vincristine in P388 leukemia by various polycyclic clinical drugs, with a special emphasis on quinacrine.
Inaba M; Maruyama E
Cancer Res; 1988 Apr; 48(8):2064-7. PubMed ID: 3349478
[TBL] [Abstract][Full Text] [Related]
19. [Enhancement of the effects of anticancer agents on B16 melanoma cells by combination with cepharanthine--I. Alkaloids].
Kubota R; Kubota K; Yamada S
Gan To Kagaku Ryoho; 1992 Nov; 19(13):2163-7. PubMed ID: 1444481
[TBL] [Abstract][Full Text] [Related]
20. [Modification of antitumor effect of vincristine by natural avermectins].
Driniaev VA; Mosin VA; Krugliak EB; Sterlina TC; Novik TC; Ermakova NV; Kublik LN; Levitman MKh; Shaposhnikova VV; Korystov IuN
Antibiot Khimioter; 2004; 49(6):3-5. PubMed ID: 15628794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
